PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
0.49%
Positive gross profit growth while TRAW is negative. John Neff would see a clear operational edge over the competitor.
56.85%
EBIT growth 50-75% of TRAW's 100.00%. Martin Whitman would suspect suboptimal resource allocation.
54.90%
Positive operating income growth while TRAW is negative. John Neff might view this as a competitive edge in operations.
56.85%
Positive net income growth while TRAW is negative. John Neff might see a big relative performance advantage.
56.86%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
56.86%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while TRAW is at 129.98%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while TRAW is at 129.98%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
28.81%
Positive OCF growth while TRAW is negative. John Neff would see this as a clear operational advantage vs. the competitor.
28.81%
Positive FCF growth while TRAW is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while TRAW stands at 1721790.68%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.99%
10Y OCF/share CAGR 1.25-1.5x TRAW's 77.68%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
56.40%
Positive OCF/share growth while TRAW is negative. John Neff might see a comparative advantage in operational cash viability.
-114.69%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
96.39%
Similar net income/share CAGR to TRAW's 98.31%. Walter Schloss would see parallel tailwinds or expansions for both firms.
45.76%
Positive 5Y CAGR while TRAW is negative. John Neff might view this as a strong mid-term relative advantage.
32.63%
Positive short-term CAGR while TRAW is negative. John Neff would see a clear advantage in near-term profit trajectory.
-96.80%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-86.34%
Negative 5Y equity/share growth while TRAW is at 10162.80%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-81.50%
Negative 3Y equity/share growth while TRAW is at 7609.85%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Negative asset growth while TRAW invests at 81849.33%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-26.00%
We have a declining book value while TRAW shows 59775.48%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-9.98%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-36.64%
Our R&D shrinks while TRAW invests at 91320.59%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-70.64%
We cut SG&A while TRAW invests at 61301.60%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.